Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maya Bucher

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Annales De Pathologie|November 28, 2006
[Leiomyomatosis peritonealis disseminata: immunohistochemical profile and origin]Maya Bucher, Marc Pusztaszeri, Hanifa Bouzourene
Revue Medicale Suisse|July 15, 2021
[Sports dermatology]Sarah Norrenberg, Maya Bucher, Christos Karatzios, et al.
Case Reports in Dermatology|April 8, 2014
Purpura of the face and neck: an atypical clinical presentation revealing a hepatosplenic T cell lymphomaFrançois Kuonen, Maya Bucher, Laurence de Leval, et al.
Melanoma Research|September 5, 2014
Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patientSolange Peters, Hasna Bouchaab, Stefan Zimmerman, et al.
Investigative Ophthalmology & Visual Science|June 28, 2019
Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways InhibitionIkram El Zaoui, Maya Bucher, Donata Rimoldi, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Annales De Pathologie|November 28, 2006
[Leiomyomatosis peritonealis disseminata: immunohistochemical profile and origin]Maya Bucher, Marc Pusztaszeri, Hanifa Bouzourene
Revue Medicale Suisse|July 15, 2021
[Sports dermatology]Sarah Norrenberg, Maya Bucher, Christos Karatzios, et al.
Case Reports in Dermatology|April 8, 2014
Purpura of the face and neck: an atypical clinical presentation revealing a hepatosplenic T cell lymphomaFrançois Kuonen, Maya Bucher, Laurence de Leval, et al.
Melanoma Research|September 5, 2014
Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patientSolange Peters, Hasna Bouchaab, Stefan Zimmerman, et al.
Investigative Ophthalmology & Visual Science|June 28, 2019
Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways InhibitionIkram El Zaoui, Maya Bucher, Donata Rimoldi, et al.
Pageof 1